Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

318 ARTÍCULOS , VIENDO DEL 16 AL 30

Nanotechnology for neurodegenerative disorders

Re F, Gregori M, Masserini M.

Maturitas. 2012 Sep;73(1):45-51. doi: 10.1016/j.maturitas.2011.12.015. Epub 2012 Jan 17.

Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial

Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P.

J Alzheimers Dis. 2012;29(2):459-69. doi: 10.3233/JAD-2011-111616.

Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD

Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, Michelson D.

Curr Alzheimer Res. 2012 May;9(4):481-90. doi: 10.2174/156720512800492530.

Neurosteroid PREGS protects neurite growth and survival of newborn neurons in the hippocampal dentate gyrus of APPswe/PS1dE9 mice

Xu B, Yang R, Chang F, Chen L, Xie G, Sokabe M, Chen L.

Curr Alzheimer Res. 2012 Mar;9(3):361-72. doi: 10.2174/156720512800107591.

Personality characteristics of staff in elderly care-a cross-cultural comparison

Richter J, Aström S, Isaksson U.

Issues Ment Health Nurs. 2012 Feb;33(2):96-100. doi: 10.3109/01612840.2011.624675.

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Curr Drug Targets. 2012 Apr;13(4):483-94. doi: 10.2174/138945012799499794.

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F.

Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93.

3-(2,4-dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer's disease?

Zawieja P, Kornprobst JM, Métais P.

Geriatr Gerontol Int. 2012 Jul;12(3):365-71. doi: 10.1111/j.1447-0594.2011.00827.x. Epub 2012 Feb 2.

Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression

Mielke MM, Leoutsakos JM, Corcoran CD, Green RC, Norton MC, Welsh-Bohmer KA, Tschanz JT, Lyketsos CG.

Alzheimers Dement. 2012 May;8(3):180-7. doi: 10.1016/j.jalz.2011.02.011. Epub 2012 Feb 1.

A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies

Sun N, Funke SA, Willbold D.

Mini Rev Med Chem. 2012 May;12(5):388-98. doi: 10.2174/138955712800493942.

QSAR applications during last decade on inhibitors of acetylcholinesterase in Alzheimer's disease

Wong KY, Duchowicz PR, Mercader AG, Castro EA.

Mini Rev Med Chem. 2012 Sep 1;12(10):936-46. doi: 10.2174/138955712802762365.

Which are the antibodies to watch in 2012?

Reichert JM.

MAbs. 2012 Jan-Feb;4(1):1-3. doi: 10.4161/mabs.4.1.18719.

Progressive and unconventional pharmacotherapeutic approaches to Alzheimer's disease therapy

Maudsley S, Chadwick W.

Curr Alzheimer Res. 2012 Jan;9(1):1-4. doi: 10.2174/156720512799015082.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias